Oncopeptides AB

ONCO · Nasdaq Stockholm · Healthcare

2.11SEK −2.6%last day

Price as of 2 October 2026

The price over the past year, with dividends: −60.9%

Performance

1 month

+11.5%

1 year

−60.9%

3 years, per year

−38.3%

5 years, per year

−45.3%

Largest fall, 3 years

−97.8%

Below the peak now

−99.0%

Volatility, 1 year

90.1%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

31.1

Dividend yield

0.0%

Return on equity

−287.9%

Net margin

–

Market value

80 m USD

Quality, value and trend

Where Oncopeptides stands against every Nordic stock today. 100 is best.

Quality10

Profitability and a sound balance sheet over time. Better than 10% of Nordic stocks.

Value2

The price measured against earnings, assets and cash flow. Better than 2% of Nordic stocks.

Trend67

The price development over the past year. Better than 67% of Nordic stocks.

Combined10

Quality, value and trend together. Better than 10% of Nordic stocks.

About Oncopeptides

Oncopeptides AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 69 employees.

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma. The company's PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis